Background: Women with a history of hypertensive disorders of pregnancy (HDP) are nearly twice as likely to develop cardiovascular disease (CVD) as those who are normotensive during pregnancy. However, the emergence of CVD risk factors after HDP is less well-understood.
During reproductive life, approximately 15% of parous women have at least 1 pregnancy complicated by a hypertensive disorder, such as gestational hypertension or preeclampsia (1) . Growing evidence suggests that these women are nearly twice as likely as those who are normotensive during pregnancy to develop cardiovascular disease (CVD) (2) (3) (4) . Hypertensive disorders of pregnancy (HDP) may reveal subclinical CVD risk under the physiologic "stress test" of pregnancy, providing early insight into CVD risk that might be leveraged to identify high-risk women for targeted prevention from an early age (1, 5) . Although the 2011 American Heart Association guidelines recommend that clinicians evaluate CVD risk by screening for a history of HDP, few data exist on which risk factors should be screened for as well as the frequency and timing of screening (6) .
Hypertensive disorders of pregnancy have been consistently linked to future chronic hypertension despite the fact that blood pressure returns to normal during the postpartum period (2, (7) (8) (9) (10) (11) (12) . Women with a history of HDP have higher risks for impaired glucose tolerance and insulin resistance and a 3-to 4-fold increased risk for type 2 diabetes mellitus (T2DM) (9, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Those with a history of preeclampsia also have higher levels of total and low-density lipoprotein cholesterol and triglycerides; however, these differences are not consistently statistically significant (16, 18 -21, 23-25) . Many previous studies were limited by small sample size; short follow-up; or incomplete adjustment for potential confounders, such as prepregnancy smoking status, body mass index (BMI), and family history. Further, although these associations have been observed over variable lengths of follow-up, little is known about the specific timing of risk factor development, which is critical to inform screening guidelines.
We examined associations of gestational hypertension and preeclampsia with development of chronic hypertension, T2DM, and hypercholesterolemia. These associations were evaluated in a large longitudinal cohort study with up to 50 years of follow-up from first birth.
Hypertensive Disorders of Pregnancy
In 2009, women retrospectively reported their complete pregnancy history. Hypertensive disorders of pregnancy were self-reported as "pregnancy-related high blood pressure" (gestational hypertension) or "preeclampsia/toxemia." The primary analysis focused on the first pregnancy because this is when HDP predominantly occurs (24).
To assess the validity of self-reported preeclampsia, we reviewed medical records of 598 women who reported preeclampsia on biennial questionnaires from 1991 to 2001 for provider report of preeclampsia or evidence of gestational hypertension (new-onset high blood pressure [systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg] after 20 weeks' gestation) and proteinuria (protein excretion ≥300 mg per 24 hours, protein-creatinine ratio ≥0.3, or dipstick reading ≥1+) (26) . There were 411 cases of preeclampsia confirmed by medical records, for a positive predictive value of 69%. Given the complexity of validating preeclampsia (confirming normotension before 20 weeks and elevated blood pressures and proteinuria after 20 weeks), several components of the medical record are required. We excluded 136 medical records with insufficient information available for validation (for example, those that were missing laboratory data or prenatal and/or labor and delivery records), resulting in a positive predictive value of 89%. Having complete medical record information for all 598 women would likely have resulted in a positive predictive value between 69% and 89%.
Recurrent HDP was analyzed in a secondary analysis with follow-up starting at age 40 years. This analysis was restricted to 45 815 parous women who had not experienced a CVD event or developed CVD risk factors of interest by age 40 years and had no additional pregnancies at this age or later.
CVD Risk Factors
Risk factors for CVD (chronic hypertension, T2DM, and hypercholesterolemia) were self-reported on biennial questionnaires beginning in 1989. The 1989 questionnaire retrospectively captured any physician diagnoses of "high blood pressure (excluding during pregnancy)," "diabetes: not during pregnancy," and "elevated cholesterol" and the year of diagnosis ("before 1980," "1980 to 1984," or "1985 to present"). Women prospectively reported incident diagnoses of CVD risk factors on biennial questionnaires beginning in 1991. The midpoint of each date range was assigned as the year of diagnosis for chronic hypertension and hypercholesterolemia; for T2DM, the year of diagnosis was obtained via a supplemental questionnaire. Previous validation of self-reported high blood pressure in NHS II indicated good agreement, with sensitivity of 94% and specificity of 85% (27) . Women who reported a new diagnosis of diabetes received a supplemental questionnaire to report diagnostic test results, symptoms, and treatment. This information was used to classify cases into categories proposed by the National Diabetes Data Group and the American Diabetes Association (28 -30). Information on self-reported use of cholesterol-lowering medication has been collected since 1999. We defined hypercholesterolemia as selfreport of hypercholesterolemia or cholesterol-lowering medication use. Self-reported hypercholesterolemia was validated in a similar cohort and showed a positive predictive value of 86% and a negative predictive value of 85% (31) .
Lifestyle Factors and Medical History
In 1989, participants reported height, current weight, and weight at age 18 years. Participants updated their weight on all biennial questionnaires. Body mass index was calculated from reported height and weight at age 18 years and was updated every 2 years from 1989 to 2013. Body mass index was derived for ages at which weight was not reported, with incorporation of data on weight at age 18 years; weights reported on each questionnaire; and somatograms at ages 20, 30, and 40 years (see the Appendix, available at Annals.org). A previous validation study in NHS II found high correlations between physical examination records and both recalled weight at age 18 years (r = 0.87) and self-reported height (r = 0.94) (32) .
Race/ethnicity, family history of chronic hypertension, and strenuous physical activity at ages 18 to 22 years were reported at baseline. History of smoking, alcohol consumption, and oral contraceptive use were also reported in 1989 and updated during follow-up. Biennial questionnaires after 1989 queried participants about family history of diabetes, parental education, and diet. Food-frequency questionnaires were used to derive a dietary quality score from the 2010 Alternative Healthy Eating Index (33) . Selfreported physician diagnoses of myocardial infarction and stroke were verified through medical record review. Prepregnancy information was drawn from the biennial Hypertensive Disorders of Pregnancy and CVD Risk Factor Development ORIGINAL RESEARCH questionnaire immediately before the first pregnancy. Because most first births (85%) occurred before baseline, health-related behavior in high school and within varying age ranges from 13 through 42 years that was retrospectively reported in 1989 was used to assign prepregnancy values for these women.
Statistical Analysis
Characteristics of the analytic sample were agestandardized and stratified by HDP status in the first pregnancy ( Table 1) . We used Cox proportional hazards models to estimate associations between HDP in the first pregnancy and chronic hypertension, T2DM, and hypercholesterolemia (28). Women contributed person-time from their first birth until development of the CVD risk factor of interest, occurrence of a CVD event (nonfatal myocardial infarction, fatal coronary heart disease, or nonfatal or fatal stroke), death, the last returned questionnaire, or 2013. They also were censored at antihypertensive medication use for the chronic hypertension analysis and at type 1 diabetes diagnosis for the T2DM analysis. For the 85% of women who delivered their first child before 1989, the analysis included an average of 9.8 years (SD, 5.5) of follow-up before enrollment.
Log-rank tests were used to determine whether the distributions of age at and time to CVD risk factor development differed between HDP groups. We calculated multivariable-adjusted hazard ratios (HRs) and 95% CIs, with adjustment for variables identified a priori as potential confounders: age at first birth; age in 1989; race/ethnicity; parental education; strenuous physical activity (at ages 18 to 22 y); family history of chronic hypertension (chronic hypertension models only) or diabetes (T2DM models only); and prepregnancy BMI, alcohol consumption, diet, smoking history, and oral contraceptive use. We assessed nonlinearity of the relationships between age at first birth and age in 1989 with each CVD risk factor by using restricted cubic splines with 10 knots at the decile medians (34 -36) . Because tests for nonlinearity were significant for the associations of age at first birth with chronic hypertension and T2DM and the association of age in 1989 with 
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Hypertensive Disorders of Pregnancy and CVD Risk Factor Development hypercholesterolemia (P < 0.001 for each), corresponding spline terms at 26 years for age at first birth and 28 years for age in 1989 were included. To evaluate departures from the proportional hazards assumption, we used restricted cubic splines to examine the extent to which the effect of HDP on CVD risk factors was modified by the number of years since the first birth. The proportional hazards assumption did not hold for any model in Table 2 (P < 0.001 for each test); therefore, HRs were also presented within 5-year intervals ( Table  3) . We investigated the presence of effect modification by preterm delivery (<37 weeks) by using a likelihood ratio test, comparing a model with multiplicative interaction terms between gestational hypertension and preterm delivery and between preeclampsia and preterm delivery to a model without these terms. Multivariable-adjusted cumulative incidence curves for each CVD risk factor by HDP status in the first pregnancy were obtained using the Breslow estimator at the mean and mode values of the continuous and categorical covariates, respectively. To address violation of the proportional hazards assumption, time-varying multiplicative interaction terms between HDP status in the first pregnancy and time since the first birth were included. All analyses were conducted using SAS, version 9.4 (SAS Institute).
Role of the Funding Source
The National Institutes of Health had no role in the design, conduct, analysis, or reporting of the study.
RESULTS

HDP in First Pregnancy and CVD Risk Factors
First births occurred between 1964 and 2008 at a mean age of 26.8 years (SD, 4.6). A total of 5386 women (9.2%) experienced HDP in their first pregnancy; 2.9% developed gestational hypertension, and 6.3% developed preeclampsia. Women with HDP in their first pregnancy and those who were normotensive during pregnancy generally had similar demographic and lifestyle characteristics (Table 1) ; however, women with HDP were more likely to have a family history of chronic hypertension and had fewer children. By the end of follow-up in 2013 (Appendix), 33.3% of women had developed chronic hypertension, 6.4% had developed T2DM, and 55.6% had developed hypercholesterolemia.
In models adjusted for age, race/ethnicity, and parental education, women with HDP in their first pregnancy developed chronic hypertension, T2DM, and hypercholesterolemia at higher rates than those who were normotensive during their first pregnancy ( Table  2) . Hazard ratios were modestly attenuated but re- The Figure shows the multivariable-adjusted cumulative incidence of chronic hypertension, T2DM, and hypercholesterolemia by HDP status in the first pregnancy through 40 years after the first birth. Women with gestational hypertension or preeclampsia had a higher cumulative incidence of all CVD risk factors than those who were normotensive during pregnancy. Women with HDP also developed the CVD risk factors sooner after their first pregnancy (P < 0.001) (Figure) and at earlier ages than those who were normotensive during pregnancy (P < 0.001) ( Table 2) . Table 3 shows the relationship between HDP in the first pregnancy and CVD risk factors, stratified by 5-year intervals through 40 years since first birth. Hazard ratios for chronic hypertension were highest in the first 5 years; compared with women who were normotensive during their first pregnancy, those with gestational hypertension had a 4.3-fold increased rate (CI, 3.2 to 5.8) and those with preeclampsia had a 4.0-fold increased rate (CI, 3.1 to 5.1). Although women with HDP had , <2 y, 2 to 3 y, or ≥4 y), and family history of chronic hypertension (yes or no; chronic hypertension model only) and type 2 diabetes mellitus (yes or no; type 2 diabetes mellitus model only). Because of small cell counts, women with missing prepregnancy smoking status (n = 352), strenuous physical activity from age 18 to 22 y (n = 348), and prepregnancy alcohol consumption (n = 249) were excluded from the analysis for the type 2 diabetes mellitus model from 6 to 10 y. † Few cases (1 case among women with gestational hypertension and no cases among women with preeclampsia) resulted in unstable estimates for type 2 diabetes mellitus ≤5 y after the first birth.
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elevated rates of chronic hypertension throughout follow-up, the relative rate diminished over time. However, absolute rate differences were lowest in earlier years, when incidence was low, and highest in later years. The statistically significant 1.5-to 2.6-fold increased rate of T2DM among women with preeclampsia appeared as early as 6 to 10 years after their first birth and continued throughout follow-up. Women with gestational hypertension had a statistically significantly increased rate of T2DM beginning 21 to 25 years after their first birth, which ranged from 1.7-to 2.6-fold higher than for women who were normotensive during pregnancy. Women with HDP in their first pregnancy had statistically significant 1.2-to 1.8-fold increased rates of hypercholesterolemia in the interval from immediately after their first birth through 35 years (for women with preeclampsia) or 40 years (for women with gestational hypertension).
Recurrent HDP and CVD Risk Factors
We examined HDP recurrence with follow-up starting at age 40 years (Appendix Table 2 , available at Annals.org). Women with HDP in their first and second or later pregnancies had the highest rates of CVD risk factor development, with HRs ranging from 1.3 (CI, 1.2 to 1.5) for hypercholesterolemia to 3.5 (CI, 3.2 to 3.9) for chronic hypertension compared with women with 2 or more pregnancies and no HDP. Women with any HDP, regardless of which pregnancy it occurred in, had increased rates of CVD risk factor development. Further adjustment for parity did not materially alter these results. Starting follow-up at age 45 years rather than 40 years yielded slightly attenuated HRs, but significance and rank were maintained across HDP groups (data not shown). Curves were obtained at the mean and mode values for the following continuous and categorical covariates, respectively: age at first birth (27 y), age in 1989 (35 y), race/ethnicity (white), parental education (12 y), strenuous physical activity at ages 18 to 22 y (1 to 3 mo per year), prepregnancy smoking status (never), prepregnancy body mass index (normal weight [18.5 to 24.9 kg/m 2 ]), prepregnancy alcohol consumption (≤1 drink per week), prepregnancy Alternative Healthy Eating Index score (third quintile), prepregnancy oral contraceptive use (≥4 y), family history of chronic hypertension (present) (chronic hypertension model only), and family history of type 2 diabetes mellitus (absent) (type 2 diabetes mellitus model only). IQR = interquartile range. * P < 0.001 from a global test of the difference in the distribution of time to development of risk factors for cardiovascular disease between groups based on hypertensive disorder status in the first pregnancy.
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Sensitivity Analyses
The majority of women who developed a CVD risk factor during follow-up did so before reporting their pregnancy history in 2009 (73% among T2DM cases, 85% among chronic hypertension cases, and 87% among hypercholesterolemia cases). Given this and the retrospective report of HDP in 2009, we conducted a sensitivity analysis with follow-up from 2009 to 2013. Hazard ratios were attenuated but statistically significant, except for the association between preeclampsia and hypercholesterolemia (HR, 1.1 [CI, 0.9 to 1.2] ). Additional analyses that started follow-up in 1982 for chronic hypertension and hypercholesterolemia (the first year of diagnosis we could assign for these risk factors), excluded women with multiple children in their first birth (n = 819), and used an alternative clinical hypertension end point that also included antihypertensive medication use yielded similar results (data not shown). To evaluate the robustness of the results to potential unmeasured confounding, we calculated E-values using the publicly available online E-value calculator (www.hsph.harvard.edu /tyler-vanderweele/tools-and-tutorials) (37) (38) (39) . E-values for the observed point estimates ranged from 1.7 for preeclampsia and hypercholesterolemia to 3.4 for gestational hypertension and chronic hypertension (Appendix Table 3 , available at Annals.org).
DISCUSSION
Women with a history of gestational hypertension or preeclampsia in their first pregnancy developed chronic hypertension at a 2-to 3-fold higher rate and had 70% and 30% higher rates of T2DM and hypercholesterolemia, respectively, than women who were normotensive during their first pregnancy. These associations persisted even after we accounted for prepregnancy confounders, including BMI, smoking, and family history. To our knowledge, this study includes the most complete adjustment for prepregnancy confounders of the relationship between HDP and CVD risk factors, and it is also one of the largest studies with one of the longest follow-ups in the literature. Our ability to describe the trajectory of risk factor development with up to 50 years of follow-up from first birth provides insight into the timing and pathways between HDP and CVD.
This study advances our understanding of the trajectory of CVD risk after HDP. Although higher magnitudes of risk have been observed for chronic hypertension and T2DM, those studies largely did not adjust for prepregnancy confounding, followed women for less time, or had smaller samples (2, 17, 18) . Although HDP has been inconsistently related to lipid measures (24) and was not previously associated with hypercholesterolemia (8), we found associations of gestational hypertension and preeclampsia with incident hypercholesterolemia. Only 3 previous studies have analyzed the associations between preterm birth or HDP recurrence and any of these CVD risk factors (10, 11, 17) . However, one considered only the first 2 pregnancies when examining recurrence (10) , and another used antihypertensive medication use as a proxy for chronic hypertension (11). Our study found that recurrent HDP confers the highest risk for chronic hypertension and T2DM, even after adjustment for prepregnancy confounding, and is the first to reveal a relationship between recurrent HDP and hypercholesterolemia. Our findings also confirm that the increased rate of CVD risk factors is not restricted to preterm preeclampsia but occurs across all combinations of HDP and gestation length. Only a few previous studies examined blood pressure (1), chronic hypertension (9, 10, 17, 40, 41) , T2DM (9, 14, 17) , and lipid values (1) among women with a history of gestational hypertension. Our finding of a higher magnitude of chronic hypertension risk among women with gestational hypertension compared with those with preeclampsia is consistent with findings of 3 previous studies (9, 10, 40) and may suggest different pathologies in these hypertensive disorders. One previous study calculated 10-year cumulative incidence of chronic hypertension among women with and without HDP (10), but we expanded our understanding by charting the 40-year cumulative incidence of CVD risk factors in these women.
The primary limitation of our study is its reliance on self-reported HDP, which was retrospectively reported in 2009 and may result in recall bias. However, selfreported preeclampsia was validated in a subset of NHS II participants, and most had medical record evidence of preeclampsia. Gestational hypertension has not yet been validated, but the proportions of first pregnancies with gestational hypertension and preeclampsia are consistent with those seen elsewhere (24). Although HDP history was retrospectively reported, length of maternal recall has not been consistently associated with accuracy (42) .
Given that 85% of participants contributed persontime to the analysis that occurred before enrollment in NHS II, there may have been selection bias. However, on the basis of the retrospective data collected on the 1989 baseline questionnaire, we were able to assign time of onset for chronic hypertension and hypercholesterolemia cases arising between 1980 and 1989 and for all T2DM cases. Because participants were excluded if they developed chronic hypertension or hypercholesterolemia before 1980, we conducted a sensitivity analysis that excluded person-time between the first birth and 1982 (the year assigned for women who developed end points between 1980 and 1984) and obtained similar results. Although inclusion in our analysis was dependent on survival to 2009, 98.2% of NHS II participants were alive that year. Further, our sensitivity analysis that included follow-up from 2009 to 2013 found results that were consistent with those observed from first birth through 2013.
Information on confounders was also self-reported, which may have resulted in misclassification or residual confounding. However, this study included the most complete adjustment for prepregnancy confounders, and on the basis of our calculated E-values, an unmeasured confounder would need to be associated with HDP and the CVD risk factor by a magnitude of 1.7-to ORIGINAL RESEARCH Hypertensive Disorders of Pregnancy and CVD Risk Factor Development 3.4-fold above and beyond the measured confounders to explain away the observed associations. The only measured confounder of similar magnitude was prepregnancy obesity, so it is unlikely that our associations could be explained away by an unmeasured confounder. Because the NHS II cohort includes primarily white nurses, caution should be used when generalizing these findings to other populations. Although our study provided longer follow-up since first birth than many previous studies, NHS II participants were still relatively young at the end of follow-up in 2013. As the cohort ages, the relative risks associated with HDP will likely decrease as the absolute risks for CVD risk factors increase.
It is not yet clear whether HDP unmasks preexisting cardiovascular risk through the "stress test" of pregnancy or whether it induces endothelial or organ damage that alters a woman's trajectory toward development of CVD risk factors. Women who develop preeclampsia tend to have slightly higher blood pressures and a dyslipidemic profile before pregnancy, indicating that preeclampsia may reveal a subclinical trajectory toward development of chronic hypertension and hypercholesterolemia that predates pregnancy (18, 43) . Regardless of whether the relationship is correlational or causal, a history of HDP may help identify women who are at increased risk for CVD risk factors and events.
Compared with women who are normotensive during their first pregnancy, those with gestational hypertension or preeclampsia are at increased risk for chronic hypertension, T2DM, and hypercholesterolemia shortly after pregnancy. This increased risk persists for several decades. These women may benefit from lifestyle interventions and screening to reduce cardiovascular risk and delay disease onset. Just as guidelines exist to screen for T2DM among women with a history of gestational diabetes (44), our findings may inform similar guidelines on screening for CVD risk factors among women with a history of HDP. 
Chronic hypertension
Cases represented the healthiest diet category), prepregnancy oral contraceptive use (never [reference], <2 y, 2 to 3 y, or ≥4 y), and family history of chronic hypertension (yes or no; chronic hypertension model only) and type 2 diabetes mellitus (yes or no; type 2 diabetes mellitus model only). These results were drawn from 6 different models: one model with HDP and normotension in first pregnancies split out by full-term and preterm deliveries (i.e., 4 exposure categories), and another model with preeclampsia, gestational hypertension, and normotension in first pregnancies split out by full-term and preterm deliveries (i.e., 6 exposure categories) for each of the 3 CVD risk factor outcomes. The normotensive term was the reference group for all contrasts. Results for women with normotension and preterm deliveries are not shown but were obtained from the same models; fully adjusted HRs were 1.10 (95% CI, 1.04 to 1.16) for chronic hypertension, 1.20 (CI, 1.06 to 1.35) for type 2 diabetes mellitus, and 1.08 (CI, 1.03 to 1.12) for hypercholesterolemia. 
